Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Saved in:
| Title: | Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. |
|---|---|
| Authors: | Halle BR; Vanderbilt University School of Medicine, Nashville, Tennessee, USA briana.r.halle@vanderbilt.edu., Betof Warner A; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Zaman FY; Alfred Hospital, Melbourne, Victoria, Australia., Haydon A; Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia., Bhave P; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Dewan AK; Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Irlmeier R; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Mehta P; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Kurtansky NR; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lacouture ME; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hassel JC; Department of Dermatology, NCT, University Hospital Heidelberg, Heidelberg, Germany., Choi JS; Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Sosman JA; Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Chandra S; Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Otto TS; Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Sullivan R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Mooradian MJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Chen ST; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA., Dimitriou F; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Long G; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Carlino M; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia., Menzies A; Melanoma Institute Australia, North Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Johnson DB; Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Rotemberg VM; Memorial Sloan Kettering Cancer Center, New York, New York, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Oct; Vol. 9 (10). |
| Publication Type: | Journal Article; Multicenter Study; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
